Kim Linton
Impact in
-
- Lymphoma Diagnosis and Treatment
- Genetics top 2%
- Chronic Lymphocytic Leukemia Research
- Glioma Diagnosis and Treatment
Papers in
-
- Lymphoma Diagnosis and Treatment 82
- Oncology 69
- CAR-T cell therapy research 34
- Viral-associated cancers and disorders 14
- Cancer Immunotherapy and Biomarkers 10
- Co-authors
- John Radford (27 shared papers)Pam McKay (15 shared papers)Tim Illidge (9 shared papers)Kate Cwynarski (10 shared papers)David Cunningham (11 shared papers)Richard Byers (12 shared papers)Michael Roost Clausen (21 shared papers)Pieternella J. Lugtenburg (15 shared papers)
- Journals
- Blood (22 papers)Journal of Clinical Oncology (15 papers)British Journal of Haematology (12 papers)HemaSphere (10 papers)Hematological Oncology (8 papers)
- Partner nations
- United KingdomUnited StatesDenmark
In The Last Decade
Kim Linton
115 papers receiving 2.2k citations
Kim Linton's Hit Papers
Peers
Comparison fields: 5 of 92
- Pathology and Forensic Medicine 1.2k
- Genetics 542
- Oncology 1.1k
- Neurology 408
- Immunology 289
Countries citing papers authored by Kim Linton
This map shows the geographic impact of Kim Linton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kim Linton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kim Linton more than expected).
Fields of papers citing papers by Kim Linton
This network shows the impact of papers produced by Kim Linton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kim Linton. The network helps show where Kim Linton may publish in the future.
Co-authors
The 25 scholars most cited alongside Kim Linton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 122 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 236 | |
| 2 | Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study Hit paper breakdown → | 2021 | 212 |
| 3 | 2017 | 192 | |
| 4 | 2016 | 113 | |
| 5 | 2018 | 104 | |
| 6 | 2012 | 72 | |
| 7 | 2008 | 65 | |
| 8 | 2016 | 62 | |
| 9 | 2014 | 50 | |
| 10 | 2020 | 43 | |
| 11 | 2020 | 42 | |
| 12 | 2009 | 39 | |
| 13 | 2011 | 38 | |
| 14 | 2018 | 38 | |
| 15 | 2009 | 34 | |
| 16 | 2021 | 33 | |
| 17 | 2013 | 32 | |
| 18 | 2020 | 32 | |
| 19 | 2019 | 31 | |
| 20 | 2006 | 30 |
About Kim Linton
Kim Linton is a scholar working on Pathology and Forensic Medicine, Oncology, Genetics, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging, having authored 122 papers that have together received 2.2k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (82 papers), Chronic Lymphocytic Leukemia Research (37 papers), CAR-T cell therapy research (34 papers), Monoclonal and Polyclonal Antibodies Research (17 papers), Viral-associated cancers and disorders (14 papers), CNS Lymphoma Diagnosis and Treatment (12 papers), Lung Cancer Treatments and Mutations (11 papers) and Cancer Immunotherapy and Biomarkers (10 papers). The work is most often cited by research in Pathology and Forensic Medicine (1.2k citations), Genetics (542 citations), Oncology (1.1k citations), Neurology (408 citations) and Immunology (289 citations). Kim Linton has collaborated with scholars based in United Kingdom, United States and Denmark. Frequent co-authors include John Radford, Pam McKay, Tim Illidge, Kate Cwynarski, David Cunningham, Richard Byers, Michael Roost Clausen, Pieternella J. Lugtenburg, Martin Hutchings and Martine E.D. Chamuleau. Their work appears in journals such as Blood, Journal of Clinical Oncology, British Journal of Haematology, HemaSphere and Hematological Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.